Rituximab in autoimmune bullous diseases: mixed responses and adverse effects

Abstract

Adjuvant B-cell depletion by rituximab is effective in otherwise therapy-resistant bullous autoimmune disorders but may be associated with substantial adverse effects including fatal outcomes.